| Theme | The Roles of Gut Physiological Active Peptides in the Control of Nutrition and Metabolism | |
|---|---|---|
| Title | Pancreatic and Extrapancreatic Effects of GLP-1 | |
| Publish Date | 2013/06 | |
| Author | Norio Harada | Department of Diabetes and Clinical Nutrition, Graduate School of Medicine, Kyoto University |
| Author | Nobuya Inagaki | Department of Diabetes and Clinical Nutrition, Graduate School of Medicine, Kyoto University |
| [ Summary ] | Glucagon like peptide-1 (GLP-1) is major incretin secreted from L-cells in response to nutritional intake. GLP-1 potentiates glucose to induced insulin secretion by binding GLP-1 receptors to pancreatic beta-cells and increasing intracellular cAMP concentrations. GLP-1 receptors are expressed in various organs. GLP-1 receptors are expressed in the intestines, CNS, lungs, kidneys and heart. Therefore, GLP-1 has not only pancreatic effects, such as potentiation of insulin secretion, but also extra-pancreatic effects. GLP-1 decreases appetite through CNS and prevents damage to cardiac myocytes and brain cells due to ischemia. Thus, incretin based therapies (DPP-4 inhibitor, GLP-1 receptor agonist and GLP-1 analogues) may provide benefits extending beyond glycemic control and insulin secretion. | |